For Hereditary Angioedema (HAE) Patients

Help Your Patients Be Prepared to Treat HAE Attacks

Fresenius Kabi contracts with a variety of Pharmacy Partners to provide access to Icatibant Injection.

Offer your patients a cost-effective, fully substitutable, and chemically equivalent* option in treating their acute attacks. The FDA-approved generic Icatibant Injection provides your patients with a cost-effective option in treating acute attacks of HAE. Icatibant Injection manufactured by Fresenius Kabi is fully substitutable and chemically equivalent to the brand product.

Remind your hereditary angioedema (HAE) patients that they should keep two on-demand HAE treatments with them at all times – in accordance with recommendations from the World Allergy Organization and European Academy of Allergy and Clinical Immunology.8

Remind your patients to replenish their Icatibant Injection after they have had an attack. Icatibant Injection may be ordered from your pharmaceutical wholesaler. It is also available at pharmacy retailers and requires a prescription.

Unit of Sale Single Pack Three Pack
NDC Number 63323-574-86 63323-574-93
Amerisource Bergen 1025-1073 1025-1074
Cardinal 5681887 5681895
McKesson 1578392 1578376
Morris & Dickson 919126 919167

Icatibant Injection is supplied as a 3 mL prefilled, single use syringe and is available in both single- and three-syringe packages.

View All

Single-Syringe Package

Single 3 mL Prefilled Syringe and one 25G Luer lock needle

3-Syringe Package

Unit of Three: 3 mL Prefilled Syringe and one 25G Luer lock needle

About Fresenius Kabi

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion, clinical nutrition, and specialty pharmaceuticals. Our products and programs are designed to help care for critically and chronically ill patients. For more than a century, we’ve delivered innovative therapies that are safe, efficient, and affordable.

Recognized for our proven track record of quality, reliability, and consistency, we produce our medications in 90 state-of-the-art plants around the world. From essential injectable medicines to advanced systems used to maintain and protect the nation’s blood supply, our products are used to help care for critically and chronically ill patients. We’re committed to making sure that patients have accurate and transparent information as new medication options come to market.


  • [8] Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy. 2022;77(7):1961-1990.
  • *Fresenius Kabi’s Icatibant Injection is fully substitutable and chemically equivalent to Firazyr®